Genmab A/S Q1 2025 Earnings Report

Genmab A/S EPS Results

• Actual EPS: $3.05
• Consensus EPS: $1.88
• Beat/Miss: Beat by +$1.17
• One Year Ago EPS: N/A

Genmab A/S Revenue Results

• Actual Revenue: $765.14 million
• Expected Revenue: $761.09 million
• Beat/Miss: Beat by +$4.05 million
• YoY Revenue Growth: N/A

Genmab A/S Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Genmab A/S (OTCMKTS:GNMSF) is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.

Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies. Its research and development activities have contributed to medicines including DARZALEX (daratumumab) for multiple myeloma, RYBREVANT (amivantamab) for certain lung cancers, and EPKINLY (epcoritamab) for certain B-cell lymphomas. Genmab has developed these and other products through collaborations with global pharmaceutical companies, including Johnson & Johnson and AbbVie.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through research, development, partnerships and commercialization activities in Europe, North America and other regions. The company is led by President and Chief Executive Officer Jan van de Winkel, who has been associated with Genmab’s leadership since the company’s early development.